174 related articles for article (PubMed ID: 32769430)
1. Aberrant GATA3 Staining in Prostatic Adenocarcinoma: A Potential Diagnostic Pitfall.
McDonald TM; Epstein JI
Am J Surg Pathol; 2021 Mar; 45(3):341-346. PubMed ID: 32769430
[TBL] [Abstract][Full Text] [Related]
2. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
Gordetsky J; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
[TBL] [Abstract][Full Text] [Related]
3. GATA3 Positivity in Benign Radiated Prostate Glands: A Potential Diagnostic Pitfall.
Wobker SE; Khararjian A; Epstein JI
Am J Surg Pathol; 2017 Apr; 41(4):557-563. PubMed ID: 28291125
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of GATA3 in metastatic adenocarcinoma of the prostate: an important pitfall.
Lobo J; Tenace NP; Cañete-Portillo S; Carneiro I; Henrique R; Lucianò R; Harik LR; Magi-Galluzzi C
Histopathology; 2024 Feb; 84(3):507-514. PubMed ID: 37965687
[TBL] [Abstract][Full Text] [Related]
6. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
7. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
[TBL] [Abstract][Full Text] [Related]
8. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
9. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract][Full Text] [Related]
10. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
11. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
12. GATA3 expression in benign prostate glands with radiation atypia: a diagnostic pitfall.
Tian W; Dorn D; Wei S; Sanders RD; Matoso A; Shah RB; Gordetsky J
Histopathology; 2017 Jul; 71(1):150-155. PubMed ID: 28316088
[TBL] [Abstract][Full Text] [Related]
13. Carcinoma of the Uterine Cervix Involving the Genitourinary Tract: A Potential Diagnostic Dilemma.
Schwartz LE; Khani F; Bishop JA; Vang R; Epstein JI
Am J Surg Pathol; 2016 Jan; 40(1):27-35. PubMed ID: 26426382
[TBL] [Abstract][Full Text] [Related]
14. Incidence and significance of GATA3 positivity in gallbladder adenocarcinoma.
Guo W; Lee W; Lu Y; Li X; Chandan VS
Hum Pathol; 2020 Dec; 106():39-44. PubMed ID: 32991930
[TBL] [Abstract][Full Text] [Related]
15. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
17. Prostatic Adenocarcinoma With Focal Pleomorphic Giant Cell Features: A Series of 30 Cases.
Alharbi AM; De Marzo AM; Hicks JL; Lotan TL; Epstein JI
Am J Surg Pathol; 2018 Oct; 42(10):1286-1296. PubMed ID: 29944471
[TBL] [Abstract][Full Text] [Related]
18. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
Osunkoya AO; Epstein JI
Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma.
Agarwal H; Babu S; Rana C; Kumar M; Singhai A; Shankhwar SN; Singh V; Sinha RJ
Indian J Pathol Microbiol; 2019; 62(2):244-250. PubMed ID: 30971548
[TBL] [Abstract][Full Text] [Related]
20. Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma.
Oh WJ; Chung AM; Kim JS; Han JH; Hong SH; Lee JY; Choi YJ
J Pathol Transl Med; 2016 Sep; 50(5):345-54. PubMed ID: 27498545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]